Details for Patent: 7,857,802
✉ Email this page to a colleague
Which drugs does patent 7,857,802 protect, and when does it expire?
Patent 7,857,802 protects NAROPIN and is included in one NDA.
This patent has twenty-three patent family members in eighteen countries.
Summary for Patent: 7,857,802
| Title: | Connector for medical liquid-containing packages and medical liquid-containing packages |
| Abstract: | The invention relates to a connector for medical liquid-containing packages, in particular to infusion or transfusion bags comprising a connection element (1) provided with a channel-shaped opening (1c) in which a self-sealing membrane (8) is arranged. A breakable part (17) which is connected to the connection piece closes the channel-shaped opening. Above the membrane (8), said connection element is embodied in the form a connection piece (13) comprising an internal cone (14) and external thread (15), the membrane (8) being sealed for receiving a syringe cone shaft. The inventive connector makes it possible to inject an active substance by means of a conventional Luer lock syringe devoid of an injection cannula (needle). |
| Inventor(s): | Brandenburger; Torsten (Niddatal, DE), Rahimy; Ismael (Friedberg, DE) |
| Assignee: | Fresenius Kabi Deutschland GmbH (Bad Homburg V.D.H., DE) |
| Application Number: | 10/575,690 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,857,802 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 7,857,802
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-006 | Sep 24, 1996 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-007 | Sep 24, 1996 | AP | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,857,802
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 103 48 016 | Oct 15, 2003 |
| PCT Information | |||
| PCT Filed | October 15, 2004 | PCT Application Number: | PCT/EP2004/011603 |
| PCT Publication Date: | April 28, 2005 | PCT Publication Number: | WO2005/037362 |
International Family Members for US Patent 7,857,802
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004281535 | ⤷ Try a Trial | |||
| Brazil | PI0415438 | ⤷ Try a Trial | |||
| Canada | 2542408 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
